Trial Profile
A Phase 1b, In-Patient Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Roluperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- 09 Feb 2024 Status changed from recruiting to completed.
- 24 Oct 2023 Status changed from planning to recruiting.
- 07 Dec 2018 New trial record